Background: A common feature of many recent trials evaluating the effects of immunotherapy on survival is that non-proportional hazards can be anticipated at the design stage. This raises the possibility to use a statistical method tailored towards testing the purported long-term benefit, rather than applying the more standard log-rank test and/or Cox model. Many such proposals have been made in recent years, but there remains a lack of practical guidance on implementation, particularly in the context of group-sequential designs. In this article, we aim to fill this gap. Methods: We illustrate how the POPLAR trial, which compared immunotherapy versus chemotherapy in non-small-cell lung cancer, might have been re-designed to be more robust t...
We consider the repeated group sequential testing of a survival endpoint with a time-varying treatme...
In clinical trials, it is important to set up a design to reach a decision on effectiveness of a dru...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...
AbstractThe semi-parametric proportional hazards model is widely adopted in randomized clinical tria...
Randomized clinical trials in oncology typically utilize time-to-event endpoints such as progression...
A challenge arising in cancer immunotherapy trial design is the presence of non-proportional hazards...
[[abstract]]We discuss logrank test-based methods for early efficacy or futility evaluation in group...
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the ...
A group-sequential (design for clinical trials that involve treatment selection was proposed by Stal...
This paper evaluates the loss of power of the simple and stratified logrank tests due to heterogenei...
The pattern of the difference between two survival curves we often observe in randomized clinical tr...
In phase II oncology trials, the use of new cytostatic drugs raises some questions regarding the end...
Background: The logrank test and the Cox proportional hazards model are routinely applied in the des...
Studies with time-to-event endpoints and small sample sizes are commonly seen; however, most statist...
Studies with time-to-event endpoints and small sample sizes are commonly seen; however, most statist...
We consider the repeated group sequential testing of a survival endpoint with a time-varying treatme...
In clinical trials, it is important to set up a design to reach a decision on effectiveness of a dru...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...
AbstractThe semi-parametric proportional hazards model is widely adopted in randomized clinical tria...
Randomized clinical trials in oncology typically utilize time-to-event endpoints such as progression...
A challenge arising in cancer immunotherapy trial design is the presence of non-proportional hazards...
[[abstract]]We discuss logrank test-based methods for early efficacy or futility evaluation in group...
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the ...
A group-sequential (design for clinical trials that involve treatment selection was proposed by Stal...
This paper evaluates the loss of power of the simple and stratified logrank tests due to heterogenei...
The pattern of the difference between two survival curves we often observe in randomized clinical tr...
In phase II oncology trials, the use of new cytostatic drugs raises some questions regarding the end...
Background: The logrank test and the Cox proportional hazards model are routinely applied in the des...
Studies with time-to-event endpoints and small sample sizes are commonly seen; however, most statist...
Studies with time-to-event endpoints and small sample sizes are commonly seen; however, most statist...
We consider the repeated group sequential testing of a survival endpoint with a time-varying treatme...
In clinical trials, it is important to set up a design to reach a decision on effectiveness of a dru...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...